Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation: A multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology-Oncology

Study Alliance of Yeungnam Pediatric Hematology-oncology (SAYPH)

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We compared transplant outcomes between donor types and stem cell sources for childhood acute myeloid leukemia (AML). The medical records of children with AML in the Yeungnam region of Korea from January 2000 to June 2017 were reviewed. In all, 76 children with AML (male-to-female ratio = 46:30) received allogenic hematopoietic stem cell transplantation (allo-HSCT). In total, 29 patients received HSCT from either a matched-related donor or a mismatched-related donor, 32 patients received an unrelated donor, and 15 patients received umbilical cord blood. In term of stem cell sources, bone marrow was used in 15 patients and peripheral blood in 46 patients. For all HSCT cases, the 5-year overall survival (OS) was 73.1% (95% CI: 62.7-83.5) and the 5-year event-free survival (EFS) was 66.1% (95% CI: 54.5-77.7). There was no statistical difference in 5-year OS according to the donor types or stem cell sources (P =.869 and P =.911). There was no statistical difference in 5-year EFS between donor types or stem cell sources (P =.526 and P =.478). For all HSCT cases, the 5-year relapse rate was 16.1% (95% CI: 7.3-24.9) and the 5-year non-relapse mortality (NRM) was 13.3% (95% CI: 5.1-21.5). There was no statistical difference in the 5-year relapse rate according to the donor types or stem cell sources (P =.971 and P =.965). There was no statistical difference in the 5-year NRM between donor types or stem cell sources (P =.461 and P =.470).

Original languageEnglish
Article numbere13249
JournalPediatric Transplantation
Volume22
Issue number6
DOIs
StatePublished - 2018 Jan 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Hematology
Acute Myeloid Leukemia
Multicenter Studies
Stem Cells
Retrospective Studies
Tissue Donors
Pediatrics
Survival
Disease-Free Survival
Recurrence
Unrelated Donors
Mortality
Korea
Fetal Blood
Medical Records
Bone Marrow
Transplants

Keywords

  • Acute myeloid leukemia
  • Children
  • Umbilical cord blood
  • Unrelated donor

Cite this

@article{9dbb01c341e24ce9860152b275bf6aa8,
title = "Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation: A multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology-Oncology",
abstract = "We compared transplant outcomes between donor types and stem cell sources for childhood acute myeloid leukemia (AML). The medical records of children with AML in the Yeungnam region of Korea from January 2000 to June 2017 were reviewed. In all, 76 children with AML (male-to-female ratio = 46:30) received allogenic hematopoietic stem cell transplantation (allo-HSCT). In total, 29 patients received HSCT from either a matched-related donor or a mismatched-related donor, 32 patients received an unrelated donor, and 15 patients received umbilical cord blood. In term of stem cell sources, bone marrow was used in 15 patients and peripheral blood in 46 patients. For all HSCT cases, the 5-year overall survival (OS) was 73.1{\%} (95{\%} CI: 62.7-83.5) and the 5-year event-free survival (EFS) was 66.1{\%} (95{\%} CI: 54.5-77.7). There was no statistical difference in 5-year OS according to the donor types or stem cell sources (P =.869 and P =.911). There was no statistical difference in 5-year EFS between donor types or stem cell sources (P =.526 and P =.478). For all HSCT cases, the 5-year relapse rate was 16.1{\%} (95{\%} CI: 7.3-24.9) and the 5-year non-relapse mortality (NRM) was 13.3{\%} (95{\%} CI: 5.1-21.5). There was no statistical difference in the 5-year relapse rate according to the donor types or stem cell sources (P =.971 and P =.965). There was no statistical difference in the 5-year NRM between donor types or stem cell sources (P =.461 and P =.470).",
keywords = "Acute myeloid leukemia, Children, Umbilical cord blood, Unrelated donor",
author = "{Study Alliance of Yeungnam Pediatric Hematology-oncology (SAYPH)} and Shim, {Ye Jee} and Lee, {Jae Min} and Kim, {Heung Sik} and Nani Jung and Lim, {Young Tak} and Yang, {Eu Jeen} and Hah, {Jeong Ok} and Young-Ho Lee and Chueh, {Hee Won} and Lim, {Jae Young} and Park, {Eun Sil} and Park, {Jeong A.} and Park, {Ji Kyoung} and Park, {Sang Kyu}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/petr.13249",
language = "English",
volume = "22",
journal = "Pediatric Transplantation",
issn = "1397-3142",
number = "6",

}

TY - JOUR

T1 - Comparison of survival outcome between donor types or stem cell sources for childhood acute myeloid leukemia after allogenic hematopoietic stem cell transplantation

T2 - A multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology-Oncology

AU - Study Alliance of Yeungnam Pediatric Hematology-oncology (SAYPH)

AU - Shim, Ye Jee

AU - Lee, Jae Min

AU - Kim, Heung Sik

AU - Jung, Nani

AU - Lim, Young Tak

AU - Yang, Eu Jeen

AU - Hah, Jeong Ok

AU - Lee, Young-Ho

AU - Chueh, Hee Won

AU - Lim, Jae Young

AU - Park, Eun Sil

AU - Park, Jeong A.

AU - Park, Ji Kyoung

AU - Park, Sang Kyu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We compared transplant outcomes between donor types and stem cell sources for childhood acute myeloid leukemia (AML). The medical records of children with AML in the Yeungnam region of Korea from January 2000 to June 2017 were reviewed. In all, 76 children with AML (male-to-female ratio = 46:30) received allogenic hematopoietic stem cell transplantation (allo-HSCT). In total, 29 patients received HSCT from either a matched-related donor or a mismatched-related donor, 32 patients received an unrelated donor, and 15 patients received umbilical cord blood. In term of stem cell sources, bone marrow was used in 15 patients and peripheral blood in 46 patients. For all HSCT cases, the 5-year overall survival (OS) was 73.1% (95% CI: 62.7-83.5) and the 5-year event-free survival (EFS) was 66.1% (95% CI: 54.5-77.7). There was no statistical difference in 5-year OS according to the donor types or stem cell sources (P =.869 and P =.911). There was no statistical difference in 5-year EFS between donor types or stem cell sources (P =.526 and P =.478). For all HSCT cases, the 5-year relapse rate was 16.1% (95% CI: 7.3-24.9) and the 5-year non-relapse mortality (NRM) was 13.3% (95% CI: 5.1-21.5). There was no statistical difference in the 5-year relapse rate according to the donor types or stem cell sources (P =.971 and P =.965). There was no statistical difference in the 5-year NRM between donor types or stem cell sources (P =.461 and P =.470).

AB - We compared transplant outcomes between donor types and stem cell sources for childhood acute myeloid leukemia (AML). The medical records of children with AML in the Yeungnam region of Korea from January 2000 to June 2017 were reviewed. In all, 76 children with AML (male-to-female ratio = 46:30) received allogenic hematopoietic stem cell transplantation (allo-HSCT). In total, 29 patients received HSCT from either a matched-related donor or a mismatched-related donor, 32 patients received an unrelated donor, and 15 patients received umbilical cord blood. In term of stem cell sources, bone marrow was used in 15 patients and peripheral blood in 46 patients. For all HSCT cases, the 5-year overall survival (OS) was 73.1% (95% CI: 62.7-83.5) and the 5-year event-free survival (EFS) was 66.1% (95% CI: 54.5-77.7). There was no statistical difference in 5-year OS according to the donor types or stem cell sources (P =.869 and P =.911). There was no statistical difference in 5-year EFS between donor types or stem cell sources (P =.526 and P =.478). For all HSCT cases, the 5-year relapse rate was 16.1% (95% CI: 7.3-24.9) and the 5-year non-relapse mortality (NRM) was 13.3% (95% CI: 5.1-21.5). There was no statistical difference in the 5-year relapse rate according to the donor types or stem cell sources (P =.971 and P =.965). There was no statistical difference in the 5-year NRM between donor types or stem cell sources (P =.461 and P =.470).

KW - Acute myeloid leukemia

KW - Children

KW - Umbilical cord blood

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=85056579004&partnerID=8YFLogxK

U2 - 10.1111/petr.13249

DO - 10.1111/petr.13249

M3 - Article

AN - SCOPUS:85056579004

VL - 22

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 6

M1 - e13249

ER -